Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Fruquintinib + Metronidazole for Third-line MSS/MSI-L Advanced Colorectal Cancer with High Fusobacterium nucleatum
ChiCTR2500096485Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, fruquintinib and metronidazole in colorectal cancer (CRC), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
tislelizumabfruquintinibmetronidazole
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500096485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096485.